Pharmacokinetic parameters of bromperidol in Korean subjects.
We have presented pharmacokinetic parameters of bromperidol (BP) in 14 healthy Korean subjects. Additionally, we have investigated the effects of dose and genetic polymorphisms on BP metabolism and on extrapyramidal symptoms (EPS). The T(max) (3.9 +/- 0.9 h), clearance (1.37 +/- 0.52 ml/h/kg), and t(1/2) (20.4 +/- 3.7 h) obtained in our study are comparable to those in previous Caucasian studies, although pharmacokinetic profiles were affected by the BP dose. We could not prove any significant correlations between BP metabolism or adverse effects and genetic factors because the number of subjects was small. Further studies with a larger population are needed to determine the influence of genetic factors on BP therapy.
Lee
Soo-Youn
SY
Department of Laboratory Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim
Yoon Gyoon
YG
Kim
Hyung-Gun
HG
Kim
Jong-Won
JW
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004421:Dystonia / Q000139:chemically induced; D005260:Female; D005838:Genotype; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D007723:Korea; D008297:Male; D012016:Reference Values
D014150:Antipsychotic Agents; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; D006220:Haloperidol; C006820:bromperidol